{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:40:25Z","timestamp":1794955225342,"version":"4.9.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMUDK109002"],"award-info":[{"award-number":["KMUDK109002"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-TC108B07"],"award-info":[{"award-number":["KMU-TC108B07"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-TCA04-3"],"award-info":[{"award-number":["KMU-TCA04-3"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s12072-020-10105-2","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T17:25:14Z","timestamp":1607102714000},"page":"1023-1033","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort"],"prefix":"10.1007","volume":"14","author":[{"name":"For the REAL-C Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Won","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hao","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Chun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Furusyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lun","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Iio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Pui-Mei","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Haga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen L.","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Bong","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nakamuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang Han","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Seon","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansen","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsey","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-4989","authenticated-orcid":false,"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"10105_CR1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s12072-019-09974-z","volume":"13","author":"CF Huang","year":"2019","unstructured":"Huang CF, Iio E, Jun DW, et al. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatol Int. 2019;13:587\u201398.","journal-title":"Hepatol Int"},{"key":"10105_CR2","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/lt.25320","volume":"24","author":"AS Bodzin","year":"2018","unstructured":"Bodzin AS, Baker TB. Liver transplantation today: where we are now and where we are going. Liver Transpl. 2018;24:1470\u20135.","journal-title":"Liver Transpl"},{"key":"10105_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/liv.13555","volume":"38","author":"C Zhao","year":"2018","unstructured":"Zhao C, Jin M, Le RH, et al. Poor adherence to hepatocellular carcinoma surveillance: a systematic review and meta-analysis of a complex issue. Liver Int. 2018;38:503\u201314.","journal-title":"Liver Int"},{"key":"10105_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"10105_CR5","unstructured":"Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer tomorrow. In: Lyon, France: International Agency for Research on Cancer; 2018."},{"key":"10105_CR6","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","volume":"157","author":"GN Ioannou","year":"2019","unstructured":"Ioannou GN, Beste LA, Green PK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157:1264-1278 e1264.","journal-title":"Gastroenterology"},{"key":"10105_CR7","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jhep.2016.10.028","volume":"66","author":"NZ Janjua","year":"2017","unstructured":"Janjua NZ, Chong M, Kuo M, et al. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol. 2017;66:504\u201313.","journal-title":"J Hepatol"},{"key":"10105_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/hep.30823","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal F, Kramer JR, Asch SM, et al. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology. 2020;71:44\u201355.","journal-title":"Hepatology"},{"key":"10105_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jhep.2016.10.017","volume":"66","author":"AJ van der Meer","year":"2017","unstructured":"van der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017;66:485\u201393.","journal-title":"J Hepatol"},{"key":"10105_CR10","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1002\/hep.30988","volume":"71","author":"H Dang","year":"2020","unstructured":"Dang H, Yeo YH, Yasuda S, et al. Cure with interferon-free direct-acting antiviral is associated with increased survival in patients with hepatitis C virus-related hepatocellular carcinoma from both east and west. Hepatology. 2020;71:1910\u201322.","journal-title":"Hepatology"},{"key":"10105_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12072-019-09939-2","volume":"13","author":"T Ide","year":"2019","unstructured":"Ide T, Koga H, Nakano M, et al. Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study. Hepatol Int. 2019;13:293\u2013301.","journal-title":"Hepatol Int"},{"key":"10105_CR12","doi-asserted-by":"publisher","unstructured":"Ogawa E, Toyoda H, Iio E, et al. HCV cure rates are reduced in patients with active but not inactive hepatocellular carcinoma- a practice implication. Clin Infect Dis. 2019. https:\/\/doi.org\/10.1093\/cid\/ciz1160.","DOI":"10.1093\/cid\/ciz1160"},{"key":"10105_CR13","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","volume":"67","author":"R Waziry","year":"2017","unstructured":"Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67:1204\u201312.","journal-title":"J Hepatol"},{"key":"10105_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"Polaris Observatory HCVC","year":"2017","unstructured":"Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161\u201376.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10105_CR15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43:1317\u201325.","journal-title":"Hepatology"},{"key":"10105_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358\u201380.","journal-title":"Hepatology"},{"key":"10105_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317\u201370.","journal-title":"Hepatol Int"},{"key":"10105_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"RP Rosenbaum","year":"1983","unstructured":"Rosenbaum RP, Rubin BD. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41\u201355.","journal-title":"Biometrika"},{"key":"10105_CR19","first-page":"411","volume":"66","author":"MA Babyak","year":"2004","unstructured":"Babyak MA. What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med. 2004;66:411\u201321.","journal-title":"Psychosom Med"},{"key":"10105_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","volume":"155","author":"V Calvaruso","year":"2018","unstructured":"Calvaruso V, Cabibbo G, Cacciola I, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology. 2018;155:411-421 e414.","journal-title":"Gastroenterology"},{"key":"10105_CR21","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","volume":"393","author":"F Carrat","year":"2019","unstructured":"Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393:1453\u201364.","journal-title":"Lancet"},{"key":"10105_CR22","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","volume":"65","author":"F Conti","year":"2016","unstructured":"Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727\u201333.","journal-title":"J Hepatol"},{"key":"10105_CR23","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","volume":"153","author":"F Kanwal","year":"2017","unstructured":"Kanwal F, Kramer J, Asch SM, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153:996-1005 e1001.","journal-title":"Gastroenterology"},{"key":"10105_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jhep.2018.03.009","volume":"69","author":"A Romano","year":"2018","unstructured":"Romano A, Angeli P, Piovesan S, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. J Hepatol. 2018;69:345\u201352.","journal-title":"J Hepatol"},{"key":"10105_CR25","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1053\/j.gastro.2019.02.046","volume":"156","author":"AG Singal","year":"2019","unstructured":"Singal AG, Lim JK, Kanwal F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review. Gastroenterology. 2019;156:2149\u201357.","journal-title":"Gastroenterology"},{"key":"10105_CR26","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000494844","volume":"8","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka A, Kumada T, Michitaka K, et al. Newly proposed ALBI grade and ALBI-T score as tools for assessment of hepatic function and prognosis in hepatocellular carcinoma patients. Liver Cancer. 2019;8:312\u201325.","journal-title":"Liver Cancer"},{"key":"10105_CR27","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jhep.2018.07.024","volume":"69","author":"GN Ioannou","year":"2018","unstructured":"Ioannou GN, Green PK, Beste LA, et al. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. J Hepatol. 2018;69:1088\u201398.","journal-title":"J Hepatol"},{"key":"10105_CR28","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1186\/s12889-019-7987-3","volume":"19","author":"C Gilligan","year":"2019","unstructured":"Gilligan C, Anderson KG, Ladd BO, et al. Inaccuracies in survey reporting of alcohol consumption. BMC Public Health. 2019;19:1639.","journal-title":"BMC Public Health"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10105-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-020-10105-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10105-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T16:01:20Z","timestamp":1610553680000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-020-10105-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10105"],"URL":"https:\/\/doi.org\/10.1007\/s12072-020-10105-2","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"18 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"YT: Research support: Janssen, Gilead, Speaker: Gilead. CFH: Speaker: AbbVie, BMS, Gilead, Merck. YCH: Research support: Gilead, Consultation: Gilead, Speaker: AbbVie, Bristol-Myers Squibb and Gilead. ME: Speaker: AbbVie. DHL: Research support: Gilead Sciences Korea, Korea Pharma. GW: Research support: Gilead, Consultation: Gilead, Speaker: Abbott, AbbVie, BMS, Echosens, Furui, Gilead, Janssen and Roche, Research grant: Gilead. MFY: Consultation: AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceutical. YU: Research support: Gilead, AbbVie, Governmental funding for research: AMED. YE: Speaker: Gilead. MLY: Research support: Abbott, BMS, Gilead and Merck, Consultant and\/or an advisory board: Abbvie, Abbott, Ascletis, BMS, Gilead and Merck, Speaker: Abbvie, Abbott, BMS, Gilead, Merck, and IPSEN. WLC: Consultation: Gilead, AbbVie, BMS, MSD, PharmaEssentia, Speaker: Gilead, AbbVie, BMS, MSD, PharmaEssentia. CYD: Consultation: Abbvie, Speaker: AbbVie, Merck, BMS, and Gilead. MHL: Research support: The Ministry of Science and Technology, Taipei, Taiwan (105-2628-B010-003-MY4, 107-2314-B-010-004-MY2 and 107-2918-I-010-004), Consultation: Gilead. MHN: Research support: Enanta, Gilead, Pfizer, B.K. Kee Foundation, National Cancer Institute. Consultant and\/or an advisory board: Novartis, Bayer, Eisai, Intercept, Gilead, Janssen, Laboratory of Advanced Medicine, Exact Sciences, and Intercept. All other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the ethics principles of the Declaration of Helsinki in 1975, as revised in 2008, and was approved by the Institutional Review Board of Stanford University, Stanford, California, USA and at each participating study center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of ethics"}}]}}